TAGRISSO granted FDA priority review in early-stage EGFR-mutated lung cancer

This article was originally published here

While up to 30% of all patients with NSCLC may be diagnosed early enough to have potentially curative surgery, disease recurrence is still common in early-stage disease and

The post TAGRISSO granted FDA priority review in early-stage EGFR-mutated lung cancer appeared first on Pharmaceutical Business review.